COMPANY INFO
Seaport Capital, founded in 1997, is a lower middle market buyout firm specializing in investments in communication infrastructure, business and information services, and media companies. With 19 employees, the firm focuses on providing financial and operational resources to grow businesses, typically investing $10 to $40 million of equity capital in companies generating EBITDA between $3 and $15 million; their website is http://www.seaportcapital.com.
Seaport Capital is a finance and private equity firm, founded in 2001, specializing in lower middle market buyouts within communication infrastructure, business and information services, and media sectors. With 19 employees, Seaport Capital operates from its headquarters in New York and provides equity investments between $10 and $40 million to companies generating $3 to $15 million in EBITDA. The company plays an active role in supporting businesses with both financial and operational resources to fuel growth in their respective industries.
Seaport Capital has demonstrated a robust funding strategy, raising a total of $325 million across 2 funding rounds. Notable funding milestones include a $100 million Series A round aimed at product development and a $225 million Series B to drive clinical milestones and further platform innovation. The firm's funding history reflects a pattern of substantial, targeted raises intended to unlock new business phases and advance the Glyph technology platform for neuropsychiatric medicines. Seaport Capital investors include well-known venture capital and institutional partners, further solidifying their standing in the finance and venture capital landscape.
This Series B round was crucial for Seaport Capital to advance clinical milestones and further develop the Glyph technology platform for neuropsychiatric medicines. The funds raised during this round enabled the company to intensify its product pipeline and expand its market reach.
Seaport Capital’s Series A was focused on the initial launch and product development of novel neuropsychiatric medicines. The capital secured established the foundation for core research and early-stage clinical progress.
General Atlantic played a lead role in Seaport Capital's Series B round, providing significant financial fuel to support clinical and platform advancements.
As a lead investor in the Series A round, Arch Venture Partners contributed to the initial stage of product development and company launch.
Sofinnova Investments also led the Series A round, underscoring Seaport Capital’s potential in developing neuropsychiatric medicines.
Foresite Capital brought expertise in healthcare investing, reinforcing Seaport Capital’s ability to tackle ambitious clinical milestones.
T. Rowe Price Associates contributed long-term institutional capital, providing financial support and stability through the company's funding journey.
Invus participated to enhance Seaport Capital’s investment in technology platforms and business growth.
The involvement of Goldman Sachs Alternatives highlights the broad institutional interest in Seaport Capital’s innovative focus.
CPP Investments added robust financial backing with a focus on sustainable growth strategies.
Third Rock Ventures supported Seaport Capital’s scientific and technology-oriented approaches in the venture capital space.
PureTech Health’s investment played a strategic role in supporting the translation of science into high-impact solutions for neuropsychiatric medicines.
Websets is a powerful natural language search and data enrichment tool that helps you discover comprehensive funding information for any company. Whether you're researching Seaport Capital funding rounds or exploring investment data for other companies, Websets provides detailed insights into funding history, investors, and financial milestones.
With Websets, you can access detailed funding profiles, investor information, and financial data through intuitive natural language queries. Sign up now to enhance your funding research capabilities.